Short Interest in Hims & Hers Health, Inc. (NYSE:HIMS) Grows By 6.2%

Hims & Hers Health, Inc. (NYSE:HIMS) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 33,840,000 shares, an increase of 6.2% from the October 15th total of 31,870,000 shares. Approximately 19.1% of the company’s stock are short sold. Based on an average daily trading volume, of 10,980,000 shares, the days-to-cover ratio is presently 3.1 days.

Hims & Hers Health Stock Performance

Hims & Hers Health stock traded up $1.56 during trading hours on Tuesday, hitting $22.55. The company had a trading volume of 14,267,494 shares, compared to its average volume of 9,344,310. Hims & Hers Health has a 1 year low of $7.50 and a 1 year high of $30.44. The firm has a market cap of $4.93 billion, a P/E ratio of 50.46 and a beta of 1.06. The company has a 50-day moving average price of $19.90 and a two-hundred day moving average price of $18.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same period in the prior year, the firm earned ($0.04) EPS. The business’s revenue for the quarter was up 77.1% on a year-over-year basis. As a group, equities research analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on HIMS. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Piper Sandler reiterated a “neutral” rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Canaccord Genuity Group upped their target price on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $20.71.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 142,886 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98. Following the completion of the sale, the chief financial officer now owns 112,186 shares in the company, valued at $3,357,726.98. This trade represents a 56.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 2,345 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total transaction of $34,354.25. Following the transaction, the insider now directly owns 159,796 shares of the company’s stock, valued at approximately $2,341,011.40. This trade represents a 1.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 996,961 shares of company stock worth $20,256,416. 17.71% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently modified their holdings of HIMS. Quest Partners LLC grew its position in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares during the last quarter. CWM LLC grew its holdings in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the period. Arizona State Retirement System lifted its stake in shares of Hims & Hers Health by 3.0% in the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after purchasing an additional 1,173 shares in the last quarter. Victory Capital Management Inc. lifted its position in Hims & Hers Health by 6.6% during the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after acquiring an additional 1,212 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.